Researchers at VCU Massey Comprehensive Cancer Center are leading an international study that advances the understanding of ...

Oncology leaders appearing in Atlanta, Georgia, including several from Winship Cancer Institute from Emory University School of Medicine, show how NGS biomarkers and MRD reshape NSCLC and hematology ...

Tuberculosis remains a major global health threat, and symptom-based case detection fails to interrupt community transmission.1 Nearly half of tuberculosis cases are missed by current strategies, and ...

Amini: From a radiation standpoint, this has changed the landscape of our field. A large proportion of my practice is stage IV disease, where patients who are on these excellent systemic therapies are ...

Amini: The systemic landscape is constantly changing and is very exciting. It will only become more complicated for our ...

Cemiplimab monotherapy offers quality-of-life benefits over chemotherapy in patients with advanced NSCLC and PD-L1 expression ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that updated clinical and translational data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK ...

Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program ...

Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...

Background Pulmonary fibrosis (PF) caused by interstitial lung diseases (ILDs) affects up to 0.1% of the global population.